

Lowering the Cost of IVF
A comparison of Conventional and possible cost cutting strategies
employed in studies since the year 2000 to 2022: A Systemic Review
and Meta-analysis

Mugove G Madziyire

ZSOG Annual Conference & AGM

24 October 2024





- Conventional IVF is not available in both the public and private sectors of most developing countries
- Where available, it is unaffordable for most couples
- This Systemic Review and Meta-analysis (SRMA) aimed to develop methods for lowering the cost of IVF for adoption in resource-constrained settings.





# The cost drivers in conventional *IVF* include:

- Infrastructure and equipment
- Investigative procedures (hysterosalpingography(HSG), ultra-sound scan(USS), laparoscope, hormonal assays)
- laboratory infrastructure for embryological procedures
- laboratory equipment (microscopes, micromanipulators, incubators, etc)
- laboratory consumables (gases, culture medium, etc)
- drugs used in cycle manipulations (gonadotropins, gonadotropin releasing hormone (GnRH) analogues, human chorionic gonadotropin (HCG), etc)
- complications ( ovarian hyper-stimulation syndrome (OHSS), multiple pregnancies, etc).





# Strategies to lower cost include

- simplifying investigations,
- lowering the cost of ovarian stimulation,
- using simple laboratory equipment and procedures,
  - using nurse led units, and
  - lowering IVF complications





#### Simplifying ovarian stimulation is perhaps the easiest way of reducing IVF costs.

- Ovarian stimulation can be simplified by using
- natural cycle/modified natural cycle IVF(MNC/NC-IVF),
- MS IVF techniques.
- Further decreases can be achieved by
- suppressing premature ovulation with
- non-steroidal anti-inflammatory drugs (NSAIDS)
- low dose clomiphene citrate(CC)
- oral progestins e.g. duphaston





#### The International Society for Mild Approaches in Assisted Reproduction (ISMAAR)

Aim	Methodology
Single	No medication
oocyte	
Single	HCG only or with GnRH antagonist and Follicle Stimulating
oocyte	Hormone/Human Menopausal Gonadotropin(FSH/HMG) add-back
2–7	Low dose FSH/HMG, oral compounds and GnRH antagonist
oocytes	
≥8	GnRH agonist or antagonist conventional FSH/HMG dose
oocytes	
	Single oocyte Single oocyte  2-7 oocytes ≥8



- founded in 2010 advocated for affordable and accessible infertility care through
- simplifying investigative procedures,
- IVF laboratory procedures, and
- ovarian stimulation protocols (Ombelet, 2013).





### methodology

- A comprehensive search of studies done since the year 2000 on outcomes of strategies that are deemed to lower the cost of IVF was carried out using MEDLINE, CENTRAL, Cochrane, PUBMED, EMBASE, the Clinical Trials Registry and snowballing from reference lists of selected studies.
- Meta-analysis was done using Review Manager 5.3 software.





## ZIMBABWE SOCIETY OF OBSTETRICIANS & GYNAECOLOGISTS Interventions and comparators

P	Women Selected for IVF
1	Cheaper IVF investigations, Cheaper embryology laboratory techniques, NC-IVF/MNC-IVF/ Mild Stimulation IVF/low Cost IVF, egg sharing, nurse led units
С	Conventional IVF/ MNC-IVF/ Mild IVF
0	Live birth rate, Pregnancy rate, time to pregnancy
Т	January 2000 – August 2022
S	Clinical Trials OR Randomised Controlled Trials





#### Outcome measures

- i. Clinical pregnancy rate (CPR)/ cycle in this review was considered as the number of pregnancies obtained from one cycle of IVF confirmed by a serum HCG test and ultrasound presence of a gestational sac by six weeks post embryo transfer.
- ii. Ongoing pregnancy rate (OPR)/cycle in this review was defined as the number of pregnancies obtained from one cycle of IVF with evidence of a fetal heart at 12 weeks post embryo transfer.
- iii. Live birth rate (LBR)/cycle was defined as babies delivering at a viable gestation who were conceived from one cycle of IVF.
- iv. Cumulative CPR/OPR/LBR referred to the total after a defined period or a number of cycles.






#### Results





#### Figure 1: PRISMA flow diagram



```
Removed before screening:

Duplicate = 5
Ineligible = 37
(98-42)

Excluded = 7
(56-7)

Not eligible = 11
```





# Mild versus COH in Good ovarian reserve women CPR/OPR/LBR per cycle

	milo		COH	1		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year	M-H, Fixed, 95% CI
(Karimzadeh et al., 2009).	31	100	37	100	48.5%	0.76 [0.43, 1.38]	2009	-
Lou and Huang 2010	9	30	9	30	12.0%	1.00 [0.33, 3.02]	2010	
Gleicher, Weghofer and Barad, 2012	3	14	9	14	13.4%	0.15 [0.03, 0.81]	2012	
Siristatidis et al., 2017	6	41	22	71	26.1%	0.38 [0.14, 1.04]	2017	<del></del>
Ochin et al., 2018	33	65	6	65		Not estimable	2018	
Total (95% CI)		185		215	100.0%	0.61 [0.40, 0.94]		•
Total events	49		77					
Heterogeneity: $Chi^2 = 4.82$ , $df = 3$ (P = 0	),19);  2=	38%					⊢ 0,1	01 0.1 1 10 100
Test for overall effect: $Z = 2.22$ (P = 0.03	3)						U,I	Less PR mild more PR mild





### **Z.S.O.G** Mild versus COH in good ovarian reserve women CLBR

	mild		COH	ł		Odds Ratio			Odo	ls Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year		M-H, Rar	ıdom, 95	5% CI	
Heijnen et al., 2007	96	205	102	199	46.7%	0.84 [0.57, 1.24]	2007		_	•		
Zhang et al., 2016	140	285	176	279	53.3%	0.57 [0.40, 0.79]	2016		•	<u>-</u>		
Total (95% CI)		490		478	100.0%	0.68 [0.46, 1.00]			•	<b>&gt;</b>		
Total events	236		278									
Heterogeneity: Tau² = Test for overall effect:		0.01	0.1 Favours mil	d Favor	10 urs COH	100						





# Z.S.O.G Mild versus COH in poor ovarian reserve women

	mile		COH	I		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year	M-H, Fixed, 95% CI
Goswami et al., 2004	3	13	6	25	3.8%	0.95 [0.20, 4.63]	2004	
Kim et al., 2009	6	45	8	45	8.4%	0.71 [0.23, 2.25]	2009	<del></del>
Karimzadeh et al., 2011	19	79	13	80	11.9%	1.63 [0.74, 3.58]	2011	+•
Mohsen and El Din, 2013	4	30	5	30	5.2%	0.77 [0.19, 3.20]	2013	
Revelli et al., 2014	47	355	70	30		Not estimable	2014	
Youssefet al., 2017	25	195	27	199	28.2%	0.94 [0.52, 1.68]	2017	<del>-</del>
van Tilborg et al., 2017	0	0	0	0		Not estimable	2017	
Siristatidis, Salamalekis, et al., 2017	4	33	5	25	6.1%	0.55 [0.13, 2.31]	2017	<del></del>
Yu et al., 2018	12	35	34	98	14.2%	0.98 [0.44, 2.21]	2018	<del></del>
Liu et al., 2020	27	97	25	94	22.2%	1.06 [0.56, 2.01]	2020	_
Total (95% CI)		882		626	100.0%	1.00 [0.74, 1.36]		•
Total events	147		193					
Heterogeneity: $Chi^2 = 2.71$ , $df = 7$ (P = 0	$0.91$ ); $I^2 = 1$	0%					<u> </u>	
Test for overall effect: $Z = 0.02$ (P = 0.9)							0.01	1 0.1 1 10 100 Favours mild Favours COH





#### NC/MNC-IVF versus COH in POR

	NC/MI	NC	COL	Н	Odds Ratio			Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Morgia et al., 2004	7	59	7	70	48.0%	1.21 [0.40, 3.68]	2004	<del>-</del>
Polyzos et al., 2012	0	0	0	0		Not estimable	2012	
Lainas et al., 2015	12	161	5	164	52.0%	2.56 [0.88, 7.44]	2015	
Total (95% CI)		220		234	100.0%	1.79 [0.83, 3.86]		•
Total events	19		12					
Heterogeneity: Tau² =	0.00; Ch	j <b>=</b> 0,9°	1, df = 1 (	(P = 0.3)	4);   ² = 09	6		1 04 1 10 100
Test for overall effect:	Z=1.48 i	(P = 0.1)	4)				0.01	I 0.1 1 10 100 Iess PR NC/MNC more PR NC/MNC





#### NC/MNC-FET was better than Artificial cycle-FET

	MNC-F	ET	Artificial Cyc	:le - ET	Odds Ratio			Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Mounce et al., 2015	0	0	0	0		Not estimable	2015	
Mounce et al., 2015	24	72	26	73	7.7%	0.90 [0.46, 1.79]	2015	<del></del>
Guan et al., 2016	187	427	276	794	62.7%	1.46 [1.15, 1.86]	2016	<b>=</b>
Guan et al., 2016	0	0	0	0		Not estimable	2016	
Groenewoud et al., 2016	57	495	41	464	20.3%	1.34 [0.88, 2.05]	2016	+-
Groenewoud et al., 2016	0	0	0	0		Not estimable	2016	
Agha-Hosseini et al., 2018	33	85	30	85	9.3%	1.16 [0.62, 2.17]	2018	-
Total (95% CI)		1079		1416	100.0%	1.36 [1.12, 1.64]		<b>♦</b>
Total events	301		373					
Heterogeneity: Tau² = 0.00; C	chi² = 1.98	6, df = 3	(P = 0.58); l <sup>2</sup> :	= 0%			Ļ	0.01 0.1 1 10 100
Test for overall effect: Z = 3.1	3 (P = 0.0	02)						0.01 0.1 1 10 100 less PR MNC-FET more PR MNC-FET



intravaginal
culture (IVC)
/simplified
culture system
(SCS) versus
conventional
culture

- The intravaginal culture of oocytes (INVO) system had a live birth rate of 55% compared to 60% for conventional culture (p>0.5)
- the simplified culture system (SCS) had ongoing pregnancy rates (OPR) of 30% versus 36.7% for intracytoplasmic sperm injection (ICSI) (p=0.35).



- Equivalent outcomes MS versus cCOH IVF in POR women
- This is in agreement with findings from
- SRMA by Datta et al., 2021 and Song @al 2016 which found no differences in pregnancy rates (CLBR/CPR/OPR) between MS and cCOH in POR.
- the practice committee of the American Society of Reproductive Medicine in their guideline following evidence review did not show a difference in CPR between MS and cCOH protocols in POR women (ASRM, 2018).
- Polyzos and Popovic-Todorovic, 2020 did a SRMA of studies done using MS on POR women and they argued against the universal adoption of MS for all women with POR.





# Equivalent CPR in POR who got NC/MNC and cCOH

- NC/MNC IVF with the low success rate of 6.1 13.7% should be offered to those women who cannot afford cCOH or MS or be the main protocol in low resource public centers.
- Pelink who did a retrospective study on such women found a CPR/cycle of 7.9% and CLBR of 44.4% after 9 cycles (Pelinck *et al.*, 2007)





# Z.S.O.G NC/MNC-FET was superior to AC-FET

• No studies did a cost effective analysis to see whether the trade-off between CPR and cost savings would justify using NC/MNC-FET if one factors monitoring of the cycle and an HCG trigger which might be used in the later





## **Z.S.O.G** Debate - low cost versus conventional IVF

- must be viewed in terms of having some service to offer where no other option exists
- rather than the viewpoint of giving some clients a less efficacious modality of treatment.
- An assumption is made that lowering the entry cost of IVF improves access to those who could not have considered it regardless of the outcomes.
- It is debatable to come up with a pregnancy rate that will justify an intervention and might depend on what odds of success couples deem worthwhile to attempt IVF





#### Conclusion

- Invitro fertilisation can be made cheaper by adopting MS/NC/MNC stimulation protocols for women with POR.
- Women with GOR who cannot afford cCOH protocols should be offered NC, MNC, and MS protocols
- Studies must explore every step in IVF to assess cost-effectiveness to adopt methods with the most minimum cost





#### THANK YOU

Dr Mugove G Madziyire gynaemadzi@y7mail.com

